Cerevel Therapeutics downgraded by BofA Securities with a new price target

8/3/23 7:19:53 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

BofA Securities downgraded Cerevel Therapeutics from Buy to Neutral and set a new price target of $31.00 from $36.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CERE

Date	Price Target	Rating	Analyst
12/8/2023	$45.00	Outperform → Market Perform	TD Cowen
11/20/2023	$25.00	Neutral	JP Morgan
9/28/2023	$33.00	Overweight	Piper Sandler
8/3/2023	$36.00 → $31.00	Buy → Neutral	BofA Securities
5/4/2023	$30.00	Equal Weight → Overweight	Wells Fargo
4/10/2023		Outperform	TD Cowen
3/17/2023	$40.00 → $29.00	Overweight → Neutral	JP Morgan
3/16/2023	$22.00	Hold	Berenberg